Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Current Assets: 2020-2024

Historic Current Assets for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $335.8 million.

  • Arcutis Biotherapeutics' Current Assets fell 17.58% to $349.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $349.2 million, marking a year-over-year decrease of 17.58%. This contributed to the annual value of $335.8 million for FY2024, which is 1.63% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' Current Assets stood at $335.8 million, which was up 1.63% from $330.4 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Current Assets peaked at $437.4 million during FY2022, and registered a low of $292.8 million during FY2020.
  • Its 3-year average for Current Assets is $367.9 million, with a median of $335.8 million in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 37.55% in 2021, then fell by 24.46% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Current Assets (Yearly) stood at $292.8 million in 2020, then spiked by 37.55% to $402.8 million in 2021, then grew by 8.60% to $437.4 million in 2022, then decreased by 24.46% to $330.4 million in 2023, then climbed by 1.63% to $335.8 million in 2024.